Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 3 of 25
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
18.02.2022
Nalu Medical Inc. Announces $104 Million Equity Financing
Press Release
16.02.2022
Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform
Press Release
11.01.2022
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics
Press Release
15.12.2021
Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release
06.12.2021
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Press Release
02.12.2021
AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
Press Release
02.12.2021
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO-112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Press Release
15.11.2021
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology
Press Release
12.11.2021
Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC
Press Release
01.11.2021
Amphista Therapeutics Appoints CBO, Beverley Carr
Press Release
©2022 Advent Life Sciences